Multiplex Assay Kit for Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) ,etc. by FLIA (Flow Luminescence Immunoassay) 
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 450.00 US$ 468.00 US$ 494.00 US$ 528.00 US$ 563.00 US$ 615.00 US$ 693.00 US$ 866.00
- Quantity
Overview
Properties
- Product No.LMB934Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transductionTumor immunityInfection immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) and the recovery rates were calculated by comparing the measured value to the expected amount of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 94-101 | 97 |
| EDTA plasma(n=5) | 89-96 | 93 |
| heparin plasma(n=5) | 96-104 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 88-102% | 97-104% | 83-93% | 80-89% |
| EDTA plasma(n=5) | 79-93% | 94-102% | 88-96% | 82-97% |
| heparin plasma(n=5) | 79-91% | 87-101% | 88-103% | 91-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:LRG1) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Leucine Rich Alpha-2-Glycoprotein 1 (LRG1) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndromePubMed: 26351173
- Targeted proteomics predict a sustained complete-response after transarterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma: a prospective cohort studypubmed:28112944
- leucine-rich alpha-2-glycoprotein-1 is up-regulated in colorectal cancer and is a tumor promoterPubmed:29785123
- Screening and Identification of Pregnancy Zone Protein (PZP) and Leucine‐Rich Alpha‐2‐Glycoprotein (LRG) as Potential Serum Biomarkers for Early‐onset …Pubmed: 30411527
- iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemiaPubmed: 31440093
- A Three-Protein Panel to Support the Diagnosis of Sepsis in ChildrenPubmed:35329889